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Osteoporosis: 
bare bone facts
Eileen Vella BPharm (Hons), PQ Dip (Nutrition & Dietetics)
Osteoporosis is a silent systemic skeletal 
disease which commonly leads to fractures 
that can occur in the absence of trauma 
or following minimal trauma.1  Fractures 
commonly associated with this disorder are 
those involving the thoracic and lumbar 
spine, distal radius and proximal femur.2
Osteoporosis was defined by the 
World Health Organisation as “A disease 
characterised by low bone mass and 
microarchitectural deterioration of bone 
tissue, leading to enhanced bone fragility 
and a consequent increase in fracture risk”. 
Classification of osteoporosis
Osteoporosis can be defined as being 
either primary or secondary in origin.  
Primary osteoporosis is said to exist where 
there are no other contributory diseases 
present.  In women, 70% of all osteoporosis 
cases are defined as being primary, although 
the vast majority of these are due to 
post-menopausal oestrogen deficiency.5 In 
men, however, only 6% of osteoporosis 
sufferers have no known predisposing 
illness but a further 16% are known to have 
hypogonadism.5
Secondary osteoporosis is said to 
exist where a pre-existing disease can be 
identified as leading to the development 
of osteoporosis.  However, in some cases 
this may be iatrogenic i.e. through drug 
administration. Table 1 gives a summary of 
causes of secondary osteoporosis.
Factors affecting 
bone mineral density
• Physical activity: The first evidence of 
an association between physical activity 
and bone mineral density (BMD) came 
from studies of the effect of inactivity 
on bones, particularly the osteopenic 
effects of weightlessness in astronauts 
during space flights.6  Physical activity 
has also been recognised as influencing 
the attainment of peak bone mass in 
childhood and adolescence.6
• Calcium is one of the most important 
constituents of bone and adequate intake 
and absorption are required to ensure 
that enough calcium is available to fulfil 
the needs of the growing skeleton.  The 
absorption of calcium from the diet relies 
on two mechanisms.  With a high calcium 
intake most calcium is absorbed passively 
from the gut.  However, with low intakes, 
calcium absorption relies on an active 
transport system in the intestinal mucosa 
which is vitamin D dependent.  Therefore 
a low calcium intake combined with a 
low vitamin D availability would greatly 
impair the amount of calcium available 
for bone formation.  The maximal effect 
of a calcium supplement appears to occur 
with a dosage of approximately 1000mg 
per day which should take into account 
dietary intake.6  High calcium intake 
is needed in childhood to achieve the 
optimum peak bone mass and therefore 
help prevent subsequent osteoporosis.5
• Vitamin D is necessary for the normal 
absorption of calcium from the intestine, 
and hence a deficiency of this vitamin 
is a risk factor for osteoporosis.  Low 
vitamin D status is attributed to low 
dietary intake, decreased skin exposure 
to the sun, or impaired synthesis of 
vitamin D in the skin.6
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Osteoporosis has become increasingly recognised as a major health 
care problem as it is the cause of more than 2.3 million fractures 
annually in Europe and USA alone.  These fractures place an 
enormous medical and personal toll on the individual and a major 
economic burden on the nation.  Osteoporosis can be prevented, 
and once diagnosed, can be treated.  The aim of prevention 
and treatment of osteoporosis is to prevent the occurrence of 
future fractures. Lifestyle changes should be encouraged in 
high risk patients. Pharmacological interventions include the 
bisphosphonates, selective oestrogen receptor modulators, hormone 
replacement therapy (HRT), calcitonin, teriparatide, calcium and 
vitamin D supplements, and calcitriol.
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• Caffeine: dietary caffeine induces 
a negative calcium balance through 
increased urinary loss.6
• Smoking: the adverse effect of smoking 
on bone is likely to be mediated through 
changes in endogenous oestrogen 
metabolism; oestrogen production is 
decreased and metabolic clearance 
has been reported to be increased in 
smokers, but this has not been confirmed 
in all studies.6  In addition, smoking is 
known to lead to an earlier menopause 
and hence to earlier post-menopausal 
status and earlier onset of the phase of 
rapid bone loss.5 Smoking has also been 
associated with lower BMD in males.
• Alcohol is directly toxic to bone as 
it reduces bone cell proliferation and 
activity.  As well as having a direct effect 
on bone, heavy alcohol consumption 
is also associated with poor nutrition, 
decreased calcium intake, reduced 
mobility and low vitamin D, all of which 
will have a compounding effect on 
reducing bone mass through their own 
individual actions.5
• Gynaecologic variables, such as oral 
contraceptive use, parity, breastfeeding, 
age at menarche, and menstrual cycle 
irregularities have all been associated 
with BMD.6  Women with late onset of 
menarche have been reported to have 
significantly reduced peak bone mass 
and increased fracture risk.  The effects 
on bone of oligomenorrhea and periods 
of amenorrhea have been documented 
mainly in cross-sectional studies which 
reported lower values for BMD than in 
control populations.6
• Genetic factors are clearly important in 
the determination of peak bone mass and 
this appears to be the stage at which 
they exert most effect, but they could 
also be determinants of fracture risk 
which are in part independent of BMD.5  
• Thin body type: it is well recognised 
that thin individuals have lower bone 
mineral density than heavier individuals, 
and there may be multiple reasons for 
this.5  Increased weight will put more 
stress on the skeleton and help maintain 
BMD in a similar way to exercise.  
• Race: Afro-Carribean women have a 
higher BMD than white women at all 
ages due to a higher peak bone mass 
and slower rate of loss.  White women 
have a 2.5-fold greater risk of getting 
osteoporosis.
Who should be treated?
If drugs were 100% efficacious, 100% 
safe and cost-free, and patients were 
100% compliant, the answer would be to 
treat everyone and early.2  Knowledge on 
an individual’s absolute risk is central to 
making treatment decisions.  The imperative 
to intervene increases with advancing age, 
lower BMD and previous fracture, as each of 
these contributes independently to fracture 
risk.
Most therapeutic agents currently 
used to treat osteoporosis inhibit bone 
resorption.  Two exceptions include 
teriparatide, which promotes bone 
formation, and strontium ranelate, which 
has a dual mode of action.7  Selection 
should take into consideration the evidence 
for efficacy of different interventions, 
the long term effects of agents and the 
differing modes of action.  
Calcitriol
Calcitriol has been shown to decrease 
bone loss in women with osteoporosis, but 
study results differ.7 A decrease in vertebral 
fracture frequency has been demonstrated 
but no protective effect has been shown for 
hip fracture.8  Calcitriol is licensed in the 
UK for the treatment of postmenopausal 
osteoporosis.9
Table 1
Causes of secondary osteoporosis4,5
Endocrine abnormalities
Hyperthyroidism
Hyperparathyroidism
Cushing’s syndrome
Diabetes mellitus
Hypogonadism (in males)
Drugs
Glucocorticoids
Anticonvulsants
Heparin therapy (long term)
Neoplastic conditions
Multiple myeloma
Bone metastases
Others
Anorexia nervosa
Alcoholism
Chronic liver disease
Inflammatory bowel disease
Rheumatoid arthritis
Renal disease
Vitamin D deficiency
Malabsorption syndromes:
   • Post gastrectomy
   • Coeliac disease
Table 2
Advice and patient education
Advice to patients:
• Eat a healthy balanced diet with 
adequate calcium and Vitamin D 
intake
• Avoid high alcohol intake
• Eat a diet rich in fruits and 
vegetables
• Do not smoke
• Keep an active lifestyle, including 
weight bearing exercise
• Keep a healthy weight for height
• Maintain a good posture
Educate patients on:
• The dangers of falling, including 
information about periods of greatest 
risk i.e. rising too quickly after eating 
or resting 
• Awareness and reduction of home 
hazards – increasing home safety 
includes optimal lighting, elimination 
of slippery or hazardous home 
surfaces and ensuring adequate hand 
supports
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Table 3
Treatment of Osteoporosis9,13, 18-22*
Post-menopausal osteoporosis Glucocorticoid-induced osteoporosis
1st line
Oral Bisphosphonates
Alendronate Alendronate
10mg daily or 70mg once weekly For postmenopausal women not on HRT:
  10mg once daily
  Other patients: 5mg once daily
Etidronate
90-day cycles of 00mg disodium etidronate for 1 days followed by 
76 days of 500mg elemental calcium
Risedronate Risedronate
5mg daily or 5mg weekly 5mg daily
2nd line
Strontium ranelate - 2g daily HRT (dose depends on preparation used)
3rd line
Raloxifene - 60mg daily
*  A number of other drugs which are available on the local market are commonly used for the treatment 
of osteoporosis.  However, since their use is unlicensed for the treatment of postmenopausal and 
glucocorticoid-induced osteoporosis such drugs were not mentioned in this table.
Calcitonin
Calcitonin is a peptide hormone with 
antiresorptive properties in bone.10 It 
decreases further bone loss at vertebral and 
femoral sites in patients with documented 
osteoporosis but has a questionable effect 
on fracture frequency.11 Calcitonin produces 
an analgesic effect with respect to bone 
pain.12  The increase in bone density 
resulting from this therapy is significantly 
less than that achieved by alendronate or 
oestrogen, and may be limited to the spine, 
but it still has value in reducing the risk of 
fracture.11  It can be administered either 
by subcutaneous injection, intramuscular 
injection or as a nasal spray.7,9
Strontium ranelate
Strontium ranelate stimulates bone 
formation and reduces bone resorption and 
is the first of a new class of osteoporotic 
treatments. In the UK it is licensed for the 
treatment of postmenopausal osteoporosis.7 
The Scottish Medicines Consortium has 
advised (July 2005) that strontium 
ranelate should be restricted to use when 
bisphosphonates are contra-indicated or 
not tolerated and then only in women aged 
over 75 years with a previous fracture and 
low bone mineral density or in other women 
at equivalent risk.9  Avoidance of calcium-
containing foods and tablets within two 
hours of taking the strontium ranelate is 
important to avoid drug interactions and 
loss of efficacy.1  Clinical trials did not 
provide evidence of an increased incidence 
of upper gastrointestinal side effects and 
the main side effect of diarrhoea is reported 
to be short-lived.  An increased risk for 
thrombosis has been noted which is being 
investigated by the manufacturers.7
Teriparatide
Teriparatide, a recombinant, fragment 
of parathyroid hormone, has been shown 
to stimulate new bone formation by direct 
effect on osteoblasts.1, 15 It is the first 
licensed anabolic drug used to reduce the 
risk of vertebral fractures in established 
osteoporosis.7 Teriparatide is available as 
a subcutaneous injection9 and is usually 
used when the patient is resistant to other 
antiosteoporotic treatments.9, 17
Selective oestrogen receptor 
modulators 
Raloxifene is a nonsteroidal 
benzothiophene compound8 with tissue-
specific oestrogen agonist and antagonist 
actions.8,, 16  It has beneficial effects on the 
skeleton and blood lipid levels, but does 
not stimulate breast or uterine tissue.16 The 
drug has been shown to increase the risk 
of venous thromboembolism to the same 
degree as oestrogen.7 One advantage of 
raloxifene is its antagonistic action in the 
endometrium – when taken over two years, 
raloxifene did not affect endometrial depth.7
Bisphosphonates
Bisphosphonates are synthetic 
analogues of pyrophosphate which adsorb 
onto hydroxyapatite crystals in bone, 
slowing both their rate of growth and 
dissolution, and therefore reducing the 
rate of bone turnover.9 Nitrogen-containing 
bisphosphonates, such as alendronate, 
risedronate and pamidronate, may suppress 
bone resorption by a different mechanism 
from that of etidronate or clodronate, which 
do not contain nitrogen.16 Bisphosphonates 
have an important role in the prophylaxis 
and treatment of osteoporosis and 
corticosteroid-induced osteoporosis; 
alendronic acid or risedronate sodium are 
considered the drugs of choice for these 
conditions, but disodium etidronate may 
be considered if these drugs are unsuitable 
or not tolerated.9  Bisphosphonates are 
poorly absorbed by the intestine and their 
absorption is further reduced by food, 
especially if it contains calcium.  They 
should, therefore, be taken in the fasting 
state 0 to 60 minutes before a meal and 
only with water.
It is important to note that 
bisphosphonates do not work optimally 
when there is underlying vitamin D 
deficiency.7
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Oestrogens
Maintaining adequate oestrogen 
levels remains the most important way 
of maintaining adequate bone density in 
women.11 Evidence indicates that oestrogens 
reduce bone turnover and prevent bone 
loss.16 Calcium supplementation amplifies 
this effect.  Oestrogen receptors have been 
demonstrated on osteoblasts and on other 
cells in the bone microenvironment but 
the precise mechanism of oestrogen action 
is still unclear.16 The risks and benefits 
of oestrogen combined with progestogen 
treatment are complex and require the 
individual assessment of each woman. The 
CSM has advised that Hormone Replacement 
Therapy should not be considered first-
line therapy for long-term prevention of 
osteoporosis in women over 50 years of age. 
HRT is of most benefit for the prophylaxis 
of postmenopausal osteoporosis if started 
early in menopause and continued for up to 
5 years, but bone loss resumes (possibly at 
an accelerated rate) on stopping HRT.9
Conclusion
Many patients are not being given 
appropriate information about prevention, 
are not having appropriate testing to 
diagnose osteoporosis or establish 
osteoporosis risk, and once diagnosed too 
many patients are not being prescribed 
effective therapies.1  Table 2 gives a 
summary of the appropriate advice and 
education which should be given to 
patients.
The prevention of osteoporosis is 
life-long.  The risk is reduced if a healthy 
lifestyle is maintained, whilst those at 
risk of developing osteoporosis should be 
targeted and given the correct preventive 
treatment.  Once osteoporosis is diagnosed 
following a fracture, treatment should be 
given. Choice of therapy should be made 
following a full discussion with the patient, 
in which the benefits and side-effects are 
outlined, so that the patient can make an 
informed choice about his/her treatment.
• The prevention of osteoporosis begins with the acquisition of optimal bone 
mass during growth. Anything hindering the acquisition of bone mass such as 
malnutrition, should be identified and dealt with during childhood
• Lifestyle advice should be provided for optimal bone health to those at risk of 
osteoporosis
• When present, secondary causes of osteoporosis should be treated/managed
• The most appropriate treatment of osteoporosis for each particular patient should 
be determined
• Strategies which aim to reduce the risk of falls should be explored
Practice Points
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